Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZC3H12A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZC3H12A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ZC3H12A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZC3H12A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ZC3H12A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZC3H12A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000926718 | Oral cavity | LP | cellular response to starvation | 59/4623 | 156/18723 | 1.78e-04 | 1.99e-03 | 59 |
GO:005140317 | Oral cavity | LP | stress-activated MAPK cascade | 84/4623 | 239/18723 | 1.79e-04 | 2.00e-03 | 84 |
GO:004478814 | Oral cavity | LP | modulation by host of viral process | 17/4623 | 30/18723 | 1.81e-04 | 2.01e-03 | 17 |
GO:006101317 | Oral cavity | LP | regulation of mRNA catabolic process | 62/4623 | 166/18723 | 1.87e-04 | 2.06e-03 | 62 |
GO:005181713 | Oral cavity | LP | modulation of process of other organism involved in symbiotic interaction | 35/4623 | 81/18723 | 1.97e-04 | 2.16e-03 | 35 |
GO:006096414 | Oral cavity | LP | regulation of gene silencing by miRNA | 24/4623 | 49/18723 | 2.00e-04 | 2.18e-03 | 24 |
GO:006014714 | Oral cavity | LP | regulation of posttranscriptional gene silencing | 25/4623 | 52/18723 | 2.15e-04 | 2.33e-03 | 25 |
GO:004259417 | Oral cavity | LP | response to starvation | 71/4623 | 197/18723 | 2.36e-04 | 2.52e-03 | 71 |
GO:000283112 | Oral cavity | LP | regulation of response to biotic stimulus | 109/4623 | 327/18723 | 2.45e-04 | 2.60e-03 | 109 |
GO:004348717 | Oral cavity | LP | regulation of RNA stability | 62/4623 | 170/18723 | 3.94e-04 | 3.82e-03 | 62 |
GO:190122212 | Oral cavity | LP | regulation of NIK/NF-kappaB signaling | 44/4623 | 112/18723 | 4.38e-04 | 4.19e-03 | 44 |
GO:005185114 | Oral cavity | LP | modulation by host of symbiont process | 27/4623 | 60/18723 | 4.71e-04 | 4.43e-03 | 27 |
GO:003249618 | Oral cavity | LP | response to lipopolysaccharide | 112/4623 | 343/18723 | 4.90e-04 | 4.60e-03 | 112 |
GO:004348817 | Oral cavity | LP | regulation of mRNA stability | 58/4623 | 158/18723 | 4.93e-04 | 4.62e-03 | 58 |
GO:007121616 | Oral cavity | LP | cellular response to biotic stimulus | 84/4623 | 246/18723 | 5.17e-04 | 4.82e-03 | 84 |
GO:007030216 | Oral cavity | LP | regulation of stress-activated protein kinase signaling cascade | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:003582113 | Oral cavity | LP | modulation of process of other organism | 41/4623 | 106/18723 | 9.70e-04 | 8.20e-03 | 41 |
GO:003806112 | Oral cavity | LP | NIK/NF-kappaB signaling | 52/4623 | 143/18723 | 1.20e-03 | 9.66e-03 | 52 |
GO:000223718 | Oral cavity | LP | response to molecule of bacterial origin | 115/4623 | 363/18723 | 1.42e-03 | 1.13e-02 | 115 |
GO:003287216 | Oral cavity | LP | regulation of stress-activated MAPK cascade | 66/4623 | 192/18723 | 1.60e-03 | 1.23e-02 | 66 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZC3H12A | SNV | Missense_Mutation | novel | c.925N>C | p.Gly309Arg | p.G309R | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.698N>T | p.Ala233Val | p.A233V | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ZC3H12A | SNV | Missense_Mutation | novel | c.754N>A | p.Glu252Lys | p.E252K | Q5D1E8 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | | c.1711N>A | p.Ala571Thr | p.A571T | Q5D1E8 | protein_coding | tolerated(0.33) | benign(0.044) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1792N>G | p.Ser598Gly | p.S598G | Q5D1E8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1684N>A | p.Gly562Ser | p.G562S | Q5D1E8 | protein_coding | deleterious(0.04) | benign(0.219) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1457N>G | p.Ala486Gly | p.A486G | Q5D1E8 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ZC3H12A | SNV | Missense_Mutation | novel | c.574N>G | p.Pro192Ala | p.P192A | Q5D1E8 | protein_coding | tolerated(0.25) | probably_damaging(0.99) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.725C>T | p.Ser242Phe | p.S242F | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | insertion | Nonsense_Mutation | novel | c.971_972insTTGCTAAGAGTCCCCTAGCATCTTCCTGATGGTCTTTCTGCCTT | p.Glu324AspfsTer3 | p.E324Dfs*3 | Q5D1E8 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |